1. 吴阶平医学基金会科研专项资助基金项目1项，经费10万元，起止时间：2025年01月01日-2028年12月31日

2. 卫生健康科技发展促进项目一肺癌诊疗研究项目1项，经费20万元，起止时间：2025年01月01日-2028年12月31日

获得国家自然科学基金项目一项，吴阶平基金一项，csco肿瘤研究基金一项

1.     Xiong A#, Wang L#, Chen J#, Wu L#, Liu B, Yao J, Zhong H,Li J, Cheng Y, Sun Y, Ge H, Yao J, Shi Q, Zhou M, Chen B, Han Z, Wang J, Bu Q,Zhao Y, Chen J, Nie L, Li G, Li X, Yu X, Ji Y, Sun D, Ai X, Chu Q, Lin Y, HaoJ, Huang D, Zhou C, Shan J, Yang H, Liu X, Wang J, Shang Y, Mei X, Yang J, LuD, Hu M, Wang ZM, Li B, Xia M, Zhou C*. Ivonescimab versus pembrolizumab forPD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised,double-blind, phase 3 study in China. The Lancet 2025, 405(10481): 839-849. 共一排第一（IF：98.4）

2.     Li W#, Wang Y#, Xiong A#, Gao G, Song Z, Zhang Y, Huang D, Ye F, Wang Q, LiZ, Liu J, Xu C, Sun Y, Liu X, Zhou F*, Zhou C*. First-in-human, phase 1dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patientswith advanced RET-altered solid tumors. Signal Transduct Target Ther 2024,9(1): 300. 共一排第三（IF：40.8）

3.     Wang H#, Xiong A#, Chen X#, Guo J#, Tang Z#, Wu C, Ren S, Zhou C,Chen J*, Hou L*, Jiang T*. CXCR1(+) neutrophil infiltration orchestratesresponse to third-generation EGFR-TKI in EGFR mutant non-small-cell lungcancer. Signal Transduct Target Ther 2024, 9(1): 342. 共一排第二（IF：40.8）

4.     Li W#, Xiong A#, Yang N#, Fan H, Yu Q, Zhao Y, Wang Y, Meng X, WuJ, Wang Z, Liu Y, Wang X, Qin X, Lu K, Zhuang W, Ren Y, Zhang X, Yan B, LovlyCM, Zhou C*. Efficacy and Safety of Taletrectinib in Chinese Patients WithROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol2024, 42(22): 2660-2670. 共一排第二（IF：42.1）

5.     Mao C#, Xiong A#, Qian J#, Wang W, Liu Y, Zhang T, Wu Z, Ni H, LuJ, Long S, Zhao L, Chen Y, Zhou C*, Xu N*. Dual inhibition of LAG-3 and PD-1with IBI110 and sintilimab in advanced solid tumors: the first-in-human phaseIa/Ib study. J Hematol Oncol 2024, 17(1): 132. 共一排第二（IF：29.5）

6.     Xiong A#, Ren S#, Liu H, Miao L, Wang L, Chen J, Li W, LiR, Wang X, Lu Z, Wang D, Wu X, Liu Z, Xing L, Mao Y, Liu C, Zeng A, Niu H, DuY, Sun Y, Pan Y, Hu Y, Zhang X, Chen X, Ma Z, Li N, Zhang J, Zhao M, Li X, YeF, Li M, Yu G, Zhang X, Min J, Han D, Li J, Zhou C*. Efficacy and Safety ofSH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm,Open-Label, Phase 2 Trial. J Thorac Oncol. 2022 Oct;17(10):1216-1226. 共一排第一（IF：21）

7.     Zhang P#, Draz MS#, Xiong A#, Yan W, Han H*, Chen W*.Immunoengineered magnetic-quantum dot nanobead system for the isolation anddetection of circulating tumor cells. J Nanobiotechnology. 2021 Apr23;19(1):116. 共一排第三（IF：10.6）

8.     Xiong A#, Li W#, Li X#, Fan Y, Ma Z, Fang J, Xie Q, ZhuangW, Kang M, Wang J, Xu T, Xu M, Zhi L, Liu Q, Wang N, Zhou C. Efficacy andsafety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, inpatients with non-small cell lung cancer who failed platinum-basedchemotherapy: a phase II study. Eur J Cancer. 2023 Sep;190:112936. doi:10.1016/j.ejca.2023.05.024. Epub 2023 Jun 5. 共一排第一（IF：7.6）